Clinical trials: Retinal Disorders
Retinitis Pigmentosa, Cone Rod Dystrophy
Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy
This study evaluates the safety and effectiveness of the Intelligent Retinal Implants System (IRIS V2). Blind patient suffering from Retinitis Pigmentosa, Cone Rod Dystrophy, or Choroideremia are implanted with an Intelligent…
- Conditions
- Retinitis Pigmentosa, Cone Rod Dystrophy, Choroideremia
- Trial name
- IRIS 2 (NCT02670980)
- Testing
- Intelligent Retinal Implant System
- Where
- 9 sites in Austria, France and 3 more
- Volunteers
- 10 people
- Sponsor
- Science Corporation
Age Factor, Age-related Macular Degeneration
Flicker Fusion Thresholds Between Young and Old Subjects at Various Luminance Levels
The objective of this study is to determine which luminance levels yield maximum differences in critical flicker fusion (CFF) scores between younger and older normal subjects.
- Trial name
- NCT03079570
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.
X-Linked Retinitis Pigmentosa
A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)
This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a full-length AAV vector-based gene therapy targeting RPGR protein.
- Trial name
- NCT06275620
- Testing
- AGTC-501 (high dose and standard corticosteroid regimen), AGTC-501 (low dose and standard corticosteroid regimen), AGTC-501 (high dose and modified corticosteroid regimen)
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Beacon Therapeutics
Diabetes Mellitus, Diabetic Macular Edema
A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
The purpose of this study is to evaluate efficacy and safety of ASP8232 in subjects with diabetic macular edema (DME). This study will evaluate the percent change from baseline in excess central subfield thickness (CST) in the…
- Trial name
- VIDI (NCT02302079)
- Testing
- ASP8232, ranibizumab
- Where
- 21 sites in United States
- Volunteers
- 96 people
- Sponsor
- Astellas Pharma Europe B.V.
Geographic Atrophy
Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride
The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the rate of progression of geographic atrophy compared to placebo in subjects with dry age-related macular degeneration.
- Trial name
- SEATTLE (NCT01802866)
- Testing
- ACU-4429
- Where
- United States
- Volunteers
- 508 people
- Sponsor
- Kubota Vision Inc.
Neovascular (Wet) Age-Related Macular Degeneration
First in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD)
This is a first-in-human clinical trial evaluating the safety and tolerability of BETA-TT8 Ophthalmic Gel in people with wet age-related macular degeneration (AMD).
- Trial name
- BEyOND (NCT07766473)
- Testing
- BETA-TT8 ophthalmic gel 3.8% w/v
- Where
- 4 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Filamon LTD
Macular Edema
A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema
This retrospective chart review study will describe the history of patients with retinal disease with macular edema to whom OZURDEX® (dexamethasone intravitreal implant) is administered, and assess treatment patterns and visual…
- Trial name
- NCT01805323
- Testing
- Dexamethasone Intravitreal Implant
- Where
- Canada
- Volunteers
- 101 people
- Sponsor
- Allergan
Diabetic Macular Edema (DME)
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial to Evaluate the Safety, Efficacy, and Durability of a Single Intravitreal Injection of 4D-150 versus Aflibercept in Adults with Diabetic Macular Edema (4SIGHT)
- Trial name
- 4SIGHT (NCT07867080)
- Testing
- 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 87 sites in United States, China and 1 more
- Volunteers
- 514 people
- Sponsor
- 4D Molecular Therapeutics
Macular Degeneration
VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)
This study will assess the efficacy and safety of intravitreally (IVT), i.e. directly into the eye administered VEGF Trap-Eye compared with photodynamic therapy (PDT) on visual function in Chinese subjects with age-related…
- Trial name
- NCT01482910
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Visudyne
- Where
- 14 sites in China
- Volunteers
- 304 people
- Sponsor
- Bayer
AMD - Age-Related Macular Degeneration, Diabetic Macular Edema
NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients
Primary objective: To evaluate the level of agreement between the NOTAL-OCT V2.5 and a commercial OCT in the presence of fluid as identified in the OCT images, in the central 10 degrees of the macula in AMD (Age-related Macular…
- Trial name
- NCT03969303
- Testing
- Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- Notal Vision Ltd.
Macular Degeneration
A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
This is a phase III, multicenter, randomized, double-masked, active treatment-controlled study of intravitreally administered ranibizumab compared with verteporfin (Visudyne) photodynamic therapy (PDT) in treating subfoveal…
- Trial name
- NCT00061594
- Testing
- rhuFab V2 (ranibizumab)
- Where
- 82 sites in United States, Australia and 4 more
- Volunteers
- 426 people
- Sponsor
- Genentech, Inc.
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG)
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
- Conditions
- Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
- Trial name
- (PENGUIN) (NCT07354477)
- Testing
- QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Qlaris Bio, Inc.
Diabetic Retinopathy, Diabetic Macular Edema
PROTECT2: Diabetes Care - Eye Exam
The PROTECT2 pilot study is a single cohort prospective study to gather pilot data and finalize operational details of the main study.
- Trial name
- NCT03094819
- Testing
- Financial Incentive, Retinal Care DR
- Where
- United States
- Volunteers
- 4,500 people
- Sponsor
- Retinal Care Inc.
Retina Condition Followed by Fluorescein Angiography Imaging
OCT Angiography Software Evaluation Study
Comparisons for vascular structure visualization in the retina and choroid.
- Trial name
- NCT04701931
- Testing
- Maestro2 OCTA, Cirrus HD-OCT 5000, TRC-50DX
- Where
- 2 sites in United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Topcon Corporation
Macular Edema, Retinal Vein Occlusion
Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China
This study will take place in China to evaluate the safety and efficacy of OZURDEX implant 700 μg in the treatment of macular edema due to retinal vein occlusion (RVO) in patients who have never received treatment for RVO.
- Trial name
- NCT03908307
- Testing
- OZURDEX
- Where
- 9 sites in China
- Volunteers
- 150 people
- Sponsor
- Allergan
Age-Related Macular Degeneration
Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
The objectives of this study are to characterize the safety, tolerability and pharmacokinetics of pegaptanib when given as 1 or 3mg/eye intravitreous injections every 6 weeks for 54 weeks in patients with subfoveal choroidal…
- Trial name
- NCT00215670
- Testing
- pegaptanib sodium (Macugen)
- Volunteers
- 125 people
- Sponsor
- Eyetech Pharmaceuticals
Choroideremia
Efficacy and Safety of BIIB111 for the Treatment of Choroideremia
The objective of the study is to evaluate the efficacy and safety of a single sub-retinal injection of BIIB111 in participants with choroideremia (CHM).
- Trial name
- STAR (NCT03496012)
- Testing
- BIIB111
- Where
- 18 sites in United States, Canada and 6 more
- Volunteers
- 169 people
- Sponsor
- Biogen
Stargardt Disease Type 1 (STGD1)
An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease
Stargardt disease type 1 (STGD1) is a rare genetic eye condition that causes progressive vision loss, often beginning in childhood or adolescence.
- Trial name
- START (NCT07063251)
- Testing
- HG005
- Where
- China
- Volunteers
- 6 people
- Sponsor
- HuidaGene Therapeutics Co., Ltd.
Outer Retinal Degeneration, Retinitis Pigmentosa
Argus® II Retinal Prosthesis System Post-Market Surveillance Study
This post-market surveillance study is conducted in the European Economic Area where Argus II has been CE certified for use in outer retinal degeneration patients.
- Trial name
- NCT01490827
- Where
- 10 sites in Germany, Italy
- Volunteers
- 52 people
- Sponsor
- Second Sight Medical Products
Diabetic Retinopathy
AutoDx-DR Prospective Clinical Validation Study Protocol
In this study, we will prospectively evaluate the accuracy of a deep-learning based software algorithm in the detection of diabetic retinopathy from 60° wide single-field retinal fundus images.
- Trial name
- NCT04627272
- Testing
- AutoDX-DR
- Volunteers
- 1,539 people
- Sponsor
- Hill-Rom
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.